ADPO-002NP / Adipo Therapeutics - LARVOL DELTA

Notch Signaling Inhibitor ADPO-002 Upregulates UCP1 Expression in Mice and Human Adipose Tissue Explants (ADA 2025) - "The tissue was homogenized after 7 days, and UCP1 expression was quantified via ELISA (ng UCP1/mg total protein, statistics: Wilcoxon paired t test). In mice, 0.2 and 1 mg ADPO-002 NP up-regulated UCP1 mRNA expression by 23-fold (p=0.4387) and 109-fold (p=0.0043), respectively compared to the control group... The results suggest that ADPO-002 has a promising browning effect on mice iWAT and human subcutaneous and omental adipose tissue."

Preclinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus